液体活检在乳腺癌精准治疗中的应用进展及展望

张羽; 刘强

doi:10.19401/j.cnki.1007-3639.2022.08.003

您当前的位置：

首页 >

文章列表页 >

液体活检在乳腺癌精准治疗中的应用进展及展望

专家述评 | 更新时间：2025-12-31

- 液体活检在乳腺癌精准治疗中的应用进展及展望
- Advances of liquid biopsy in precision treatment of breast cancer
- 中国癌症杂志 2022年32卷第8期页码：688-697
- 作者机构：
  
  中山大学孙逸仙纪念医院乳腺肿瘤中心,广东广州 510000
- 作者简介：
  
  [ "张羽（ORCID：0000-0002-1339-8367）,中山大学孙逸仙纪念医院乳腺肿瘤中心硕士研究生,E-mail: zhangy583@mail2.sysu.edu.cn" ]
  [ "刘强,主任医师、研究员、教授、逸仙乳腺肿瘤医院执行副院长、中山大学孙逸仙纪念医院外科主任、乳腺肿瘤中心主任、乳腺外科主任。现任欧洲肿瘤学院国际年轻乳腺癌共识专家组成员,亚洲乳腺癌协作组成员,中国临床肿瘤学会乳腺癌专业委员会常务委员兼副秘书长,中国抗癌协会乳腺癌专业委员会常务委员,中国抗癌协会肿瘤分子医学专业委员会常务委员,广东省医学会乳腺病学分会主任委员,广东省抗癌协会乳腺癌专业委员会候任主任委员等。毕业于中南大学湘雅医学院和新加坡国立大学,先后任哈佛大学Dana Farber癌症中心博士后及讲师,2011年以中山大学“百人计划”引进回国。长期从事乳腺肿瘤临床及科研工作,擅长乳腺良恶性疾病的鉴别诊断、乳腺癌的手术和综合治疗,尤其高难度保乳手术和疑难乳腺癌的个体化精准治疗。先后主持多项国家级重大项目包括国家自然科学基金重点项目和973课题,在SCI收录的期刊上发表论文超过80篇。率先开展液体活检和免疫联合治疗在乳腺癌中的应用,发起和制定中国首部年轻乳腺癌专家共识,2020年获人民日报社主办的“国之名医·优秀风范”荣誉称号。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.08.003
  中图分类号： R737.9
- 收稿：2022-07-01，
  
  修回：2022-07-20，
  
  纸质出版：2022-08-30
- 稿件说明：
移动端阅览
张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022,32(8):688-697.

Yu ZHANG, Qiang LIU. Advances of liquid biopsy in precision treatment of breast cancer[J]. China Oncology, 2022, 32(8): 688-697.
张羽, 刘强. 液体活检在乳腺癌精准治疗中的应用进展及展望[J]. 中国癌症杂志, 2022,32(8):688-697. DOI： 10.19401/j.cnki.1007-3639.2022.08.003.

Yu ZHANG, Qiang LIU. Advances of liquid biopsy in precision treatment of breast cancer[J]. China Oncology, 2022, 32(8): 688-697. DOI： 10.19401/j.cnki.1007-3639.2022.08.003.

摘要

在全球范围内

乳腺癌是女性最常见的恶性肿瘤。近年来

迅速扩大的基因组学知识体系不仅揭示了恶性肿瘤的复杂性

也使得恶性肿瘤的治疗范式从以肿瘤类型为导向逐渐转向以基因为导向

根据生物标志物分析为患者进行个体化治疗。目前大量研究已证实从患者获得肿瘤分子图谱优化了癌症个性化治疗方案的选择

以及对治疗反应、耐药及肿瘤复发的监测。而液体活检

通过对体液中肿瘤衍生材料所包含的基因组等数据进行分析

可以获得关于个体患者肿瘤特征的详细信息

为基于精准医学的治疗开辟新思路。在乳腺癌精准治疗中

液体活检可以预测生存预后、检测微小残留疾病（minimal residual disease

MRD）、监测治疗效果

在（新）辅助治疗及解救治疗中发挥作用。虽然液体活检在乳腺癌精准治疗方面的研究取得了令人瞩目的进展

但是仍存在一些问题

还需要更多的工作来进一步改进技术。本文将就近年来液体活检在乳腺癌精准治疗中的应用研究进展进行综述

并对未来的发展趋势予以展望。

Abstract

Breast cancer is the most common malignant tumor in women worldwide. Recently

the complexity of malignant tumors has been revealed following the rapid expansion of the knowledge system of genomics

and the treatment of tumors has shifted from tumor type-oriented therapy to gene-oriented therapy

which is based on biomarker analysis. Great efforts have proved that tumor molecular profiles from patients are capable to improve the selection of personalized treatment options

as well as monitoring of treatment response

drug resistance and tumor recurrence. Liquid biopsy

a method to analyze the genome and other data contained in tumor-derived materials in body fluids

can obtain detailed information about the characteristics of individual patient's tumors

providing new ideas for precision treatment. In the precise treatment of breast cancer

liquid biopsy can predict survival prognosis

detect minimal residual disease (MRD)

monitor treatment efficacy

and play a role in (neo)adjuvant treatment and rescue treatment. Although the research of liquid biopsy in the precise treatment of breast cancer has made remarkable progress

there are still some problems

and more work is needed to further improve the technology. In this paper

we reviewed the research progress of liquid biopsy in the precision therapy of breast cancer in recent years

and the future trend of liquid biopsy is forecasted.

关键词

Keywords

references

SIEGEL R L , MILLER K D , JEMAL A . Cancer statistics, 2018 [J ] . CA Cancer J Clin , 2018 , 68 ( 1 ): 7 - 30 . DOI: 10.3322/caac.21442 http://doi.org/10.3322/caac.21442 http://doi.wiley.com/10.3322/caac.21442 http://doi.wiley.com/10.3322/caac.21442

LOIBL S , POORTMANS P , MORROW M , et al . Breast cancer [J ] . Lancet , 2021 , 397 ( 10286 ): 1750 - 1769 . DOI: 10.1016/S0140-6736(20)32381-3 http://doi.org/10.1016/S0140-6736(20)32381-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673620323813 https://linkinghub.elsevier.com/retrieve/pii/S0140673620323813

WHELER J , LEE J J , KURZROCK R . Unique molecular landscapes in cancer: implications for individualized, curated drug combinations [J ] . Cancer Res , 2014 , 74 ( 24 ): 7181 - 7184 . DOI: 10.1158/0008-5472.CAN-14-2329 http://doi.org/10.1158/0008-5472.CAN-14-2329 https://aacrjournals.org/cancerres/article/74/24/7181/599195/Unique-Molecular-Landscapes-in-Cancer-Implications https://aacrjournals.org/cancerres/article/74/24/7181/599195/Unique-Molecular-Landscapes-in-Cancer-Implications

TSIMBERIDOU A M , FOUNTZILAS E , NIKANJAM M , et al . Review of precision cancer medicine: evolution of the treatment paradigm [J ] . Cancer Treat Rev , 2020 , 86 : 102019 . DOI: 10.1016/j.ctrv.2020.102019 http://doi.org/10.1016/j.ctrv.2020.102019 https://linkinghub.elsevier.com/retrieve/pii/S0305737220300578 https://linkinghub.elsevier.com/retrieve/pii/S0305737220300578

KURZROCK R , GILES F J . Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes [J ] . Cell Cycle , 2015 , 14 ( 14 ): 2219 - 2221 . DOI: 10.1080/15384101.2015.1041695 http://doi.org/10.1080/15384101.2015.1041695 https://www.tandfonline.com/doi/full/10.1080/15384101.2015.1041695 https://www.tandfonline.com/doi/full/10.1080/15384101.2015.1041695

DUMBRAVA E I , MERIC-BERNSTAM F . Personalized cancer therapy-leveraging a knowledge base for clinical decision-making [J ] . Cold Spring Harb Mol Case Stud , 2018 , 4 ( 2 ): a001578.

LONE S N , NISAR S , MASOODI T , et al . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments [J ] . Mol Cancer , 2022 , 21 ( 1 ): 79 . DOI: 10.1186/s12943-022-01543-7 http://doi.org/10.1186/s12943-022-01543-7 https://doi.org/10.1186/s12943-022-01543-7 https://doi.org/10.1186/s12943-022-01543-7

TAY T K Y , TAN P H . Liquid biopsy in breast cancer: a focused review [J ] . Arch Pathol Lab Med , 2021 , 145 ( 6 ): 678 - 686 . DOI: 10.5858/arpa.2019-0559-RA http://doi.org/10.5858/arpa.2019-0559-RA https://meridian.allenpress.com/aplm/article/145/6/678/427493/Liquid-Biopsy-in-Breast-Cancer-A-Focused-Review https://meridian.allenpress.com/aplm/article/145/6/678/427493/Liquid-Biopsy-in-Breast-Cancer-A-Focused-Review

YOUNG R , PAILLER E , BILLIOT F , et al . Circulating tumor cells in lung cancer [J ] . Acta Cytol , 2012 , 56 ( 6 ): 655 - 660 . DOI: 10.1159/000345182 http://doi.org/10.1159/000345182 https://www.karger.com/Article/FullText/345182 https://www.karger.com/Article/FullText/345182

KOWALIK A , KOWALEWSKA M , GÓŹDŹ S . Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors [J ] . Transl Res , 2017 , 185 : 58 - 84 .e15. DOI: 10.1016/j.trsl.2017.04.002 http://doi.org/10.1016/j.trsl.2017.04.002 https://linkinghub.elsevier.com/retrieve/pii/S1931524416303498 https://linkinghub.elsevier.com/retrieve/pii/S1931524416303498

ANDREE K C , VAN DALUM G , TERSTAPPEN L W M M . Challenges in circulating tumor cell detection by the CellSearch system [J ] . Mol Oncol , 2016 , 10 ( 3 ): 395 - 407 . DOI: 10.1016/j.molonc.2015.12.002 http://doi.org/10.1016/j.molonc.2015.12.002 http://doi.wiley.com/10.1016/j.molonc.2015.12.002 http://doi.wiley.com/10.1016/j.molonc.2015.12.002

SEQUIST L V , NAGRATH S , TONER M , et al . The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients [J ] . J Thorac Oncol , 2009 , 4 ( 3 ): 281 - 283 . DOI: 10.1097/JTO.0b013e3181989565 http://doi.org/10.1097/JTO.0b013e3181989565 https://linkinghub.elsevier.com/retrieve/pii/S1556086415309783 https://linkinghub.elsevier.com/retrieve/pii/S1556086415309783

YANG L Y , LANG J C , BALASUBRAMANIAN P , et al . Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells [J ] . Biotechnol Bioeng , 2009 , 102 ( 2 ): 521 - 534 . DOI: 10.1002/bit.22066 http://doi.org/10.1002/bit.22066 https://onlinelibrary.wiley.com/doi/10.1002/bit.22066 https://onlinelibrary.wiley.com/doi/10.1002/bit.22066

POKLEPOVIC A S , WAN W , WU W G , et al . ApoStream, an antibody-independent platform, compared to CellSearch for enumeration of circulating tumor cells (CTCs) in patients with metastatic prostate cancer [J ] . J Clin Oncol , 2012 , 30 ( 15_suppl ): e21058.

FLEISCHHACKER M , SCHMIDT B . Circulating nucleic acids (CNAs) and cancer: a survey [J ] . Biochim Biophys Acta BBA Rev Cancer , 2007 , 1775 ( 1 ): 181 - 232 .

UNDERHILL H R , KITZMAN J O , HELLWIG S , et al . Fragment length of circulating tumor DNA [J ] . PLoS Genet , 2016 , 12 ( 7 ): e1006162.

DIEHL F , SCHMIDT K , CHOTI M A , et al . Circulating mutant DNA to assess tumor dynamics [J ] . Nat Med , 2008 , 14 ( 9 ): 985 - 990 . DOI: 10.1038/nm.1789 http://doi.org/10.1038/nm.1789 https://doi.org/10.1038/nm.1789 https://doi.org/10.1038/nm.1789

PARKINSON C A , GALE D , PISKORZ A M , et al . Exploratory analysis of TP 53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study [J ] . PLoS Med , 2016 , 13 ( 12 ): e1002198.

CHAUDHURI A A , CHABON J J , LOVEJOY A F , et al . Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling [J ] . Cancer Discov , 2017 , 7 ( 12 ): 1394 - 1403 . DOI: 10.1158/2159-8290.CD-17-0716 http://doi.org/10.1158/2159-8290.CD-17-0716 https://aacrjournals.org/cancerdiscovery/article/7/12/1394/40329/Early-Detection-of-Molecular-Residual-Disease-in https://aacrjournals.org/cancerdiscovery/article/7/12/1394/40329/Early-Detection-of-Molecular-Residual-Disease-in

SIRAVEGNA G , MARSONI S , SIENA S , et al . Integrating liquid biopsies into the management of cancer [J ] . Nat Rev Clin Oncol , 2017 , 14 ( 9 ): 531 - 548 . DOI: 10.1038/nrclinonc.2017.14 http://doi.org/10.1038/nrclinonc.2017.14 http://www.nature.com/articles/nrclinonc.2017.14 http://www.nature.com/articles/nrclinonc.2017.14

HAN X , WANG J Y , SUN Y L . Circulating tumor DNA as biomarkers for cancer detection [J ] . Genom Proteom Bioinform , 2017 , 15 ( 2 ): 59 - 72 . DOI: 10.1016/j.gpb.2016.12.004 http://doi.org/10.1016/j.gpb.2016.12.004 https://linkinghub.elsevier.com/retrieve/pii/S1672022917300487 https://linkinghub.elsevier.com/retrieve/pii/S1672022917300487

DIEHL F , LI M , DRESSMAN D , et al . Detection and quantification of mutations in the plasma of patients with colorectal tumors [J ] . Proc Natl Acad Sci USA , 2005 , 102 ( 45 ): 16368 - 16373 . DOI: 10.1073/pnas.0507904102 http://doi.org/10.1073/pnas.0507904102 https://pnas.org/doi/full/10.1073/pnas.0507904102 https://pnas.org/doi/full/10.1073/pnas.0507904102

HOLM M , ANDERSSON E , OSTERLUND E , et al . Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing [J ] . PLoS One , 2020 , 15 ( 11 ): e0239819.

LEARY R J , KINDE I , DIEHL F , et al . Development of personalized tumor biomarkers using massively parallel sequencing [J ] . Sci Transl Med , 2010 , 2 ( 20 ): 20ra14.

FORSHEW T , MURTAZA M , PARKINSON C , et al . Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA [J ] . Sci Transl Med , 2012 , 4 ( 136 ): 136ra68.

CHAN K C , JIANG P Y , ZHENG Y W , et al . Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing [J ] . Clin Chem , 2013 , 59 ( 1 ): 211 - 224 . DOI: 10.1373/clinchem.2012.196014 http://doi.org/10.1373/clinchem.2012.196014 https://academic.oup.com/clinchem/article/59/1/211/5622098 https://academic.oup.com/clinchem/article/59/1/211/5622098

LEARY R J , SAUSEN M , KINDE I , et al . Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing [J ] . Sci Transl Med , 2012 , 4 ( 162 ): 162ra154.

LUCCI A , HALL C S , LODHI A K , et al . Circulating tumour cells in non-metastatic breast cancer: a prospective study [J ] . Lancet Oncol , 2012 , 13 ( 7 ): 688 - 695 . DOI: 10.1016/S1470-2045(12)70209-7 http://doi.org/10.1016/S1470-2045(12)70209-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204512702097 https://linkinghub.elsevier.com/retrieve/pii/S1470204512702097

JANNI W J , RACK B , TERSTAPPEN L W , et al . Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer [J ] . Clin Cancer Res , 2016 , 22 ( 10 ): 2583 - 2593 . DOI: 10.1158/1078-0432.CCR-15-1603 http://doi.org/10.1158/1078-0432.CCR-15-1603 https://aacrjournals.org/clincancerres/article/22/10/2583/122011/Pooled-Analysis-of-the-Prognostic-Relevance-of https://aacrjournals.org/clincancerres/article/22/10/2583/122011/Pooled-Analysis-of-the-Prognostic-Relevance-of

CHIMONIDOU M , STRATI A , TZITZIRA A , et al . DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells [J ] . Clin Chem , 2011 , 57 ( 8 ): 1169 - 1177 . DOI: 10.1373/clinchem.2011.165902 http://doi.org/10.1373/clinchem.2011.165902 https://academic.oup.com/clinchem/article/57/8/1169/5620955 https://academic.oup.com/clinchem/article/57/8/1169/5620955

BUDD G T , CRISTOFANILLI M , ELLIS M J , et al . Circulating tumor cells versus imaging: predicting overall survival in metastatic breast cancer [J ] . Clin Cancer Res , 2006 , 12 ( 21 ): 6403 - 6409 . DOI: 10.1158/1078-0432.CCR-05-1769 http://doi.org/10.1158/1078-0432.CCR-05-1769 https://aacrjournals.org/clincancerres/article/12/21/6403/191102/Circulating-Tumor-Cells-versus-Imaging-Predicting https://aacrjournals.org/clincancerres/article/12/21/6403/191102/Circulating-Tumor-Cells-versus-Imaging-Predicting

LI S Y , LAI H N , LIU J Q , et al . Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy [J ] . JCO Precis Oncol , 2020 ( 4 ): 244 - 257 .

KIM M H , KIM G M , KIM S G , et al . Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: post-hoc analysis of phase Ⅲ PEARLY trial [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 603 . DOI: 10.1200/JCO.2022.40.16_suppl.603 http://doi.org/10.1200/JCO.2022.40.16_suppl.603 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.603 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.603

RIVA F , BIDARD F C , HOUY A , et al . Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer [J ] . Clin Chem , 2017 , 63 ( 3 ): 691 - 699 . DOI: 10.1373/clinchem.2016.262337 http://doi.org/10.1373/clinchem.2016.262337 https://academic.oup.com/clinchem/article/63/3/691/5612898 https://academic.oup.com/clinchem/article/63/3/691/5612898

MAGBANUA M J M , SWIGART L B , WU H T , et al . Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival [J ] . Ann Oncol , 2021 , 32 ( 2 ): 229 - 239 . DOI: 10.1016/j.annonc.2020.11.007 http://doi.org/10.1016/j.annonc.2020.11.007 https://linkinghub.elsevier.com/retrieve/pii/S092375342043162X https://linkinghub.elsevier.com/retrieve/pii/S092375342043162X

PAPAKONSTANTINOU A , GONZALEZ N S , PIMENTEL I , et al . Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis [J ] . Cancer Treat Rev , 2022 , 104 : 102362 . DOI: 10.1016/j.ctrv.2022.102362 http://doi.org/10.1016/j.ctrv.2022.102362 https://linkinghub.elsevier.com/retrieve/pii/S0305737222000263 https://linkinghub.elsevier.com/retrieve/pii/S0305737222000263

GARCIA-MURILLAS I , SCHIAVON G , WEIGELT B , et al . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer [J ] . Sci Transl Med , 2015 , 7 ( 302 ): 302ra133.

OLSSON E , WINTER C , GEORGE A , et al . Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease [J ] . EMBO Mol Med , 2015 , 7 ( 8 ): 1034 - 1047 . DOI: 10.15252/emmm.201404913 http://doi.org/10.15252/emmm.201404913 https://onlinelibrary.wiley.com/doi/10.15252/emmm.201404913 https://onlinelibrary.wiley.com/doi/10.15252/emmm.201404913

CRISTOFANILLI M , BUDD G T , ELLIS M J , et al . Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J ] . N Engl J Med , 2004 , 351 ( 8 ): 781 - 791 . DOI: 10.1056/NEJMoa040766 http://doi.org/10.1056/NEJMoa040766 http://www.nejm.org/doi/abs/10.1056/NEJMoa040766 http://www.nejm.org/doi/abs/10.1056/NEJMoa040766

ROSSI G , MU Z M , RADEMAKER A W , et al . Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer [J ] . Clin Cancer Res , 2018 , 24 ( 3 ): 560 - 568 . DOI: 10.1158/1078-0432.CCR-17-2092 http://doi.org/10.1158/1078-0432.CCR-17-2092 https://aacrjournals.org/clincancerres/article/24/3/560/81101/Cell-Free-DNA-and-Circulating-Tumor-Cells https://aacrjournals.org/clincancerres/article/24/3/560/81101/Cell-Free-DNA-and-Circulating-Tumor-Cells

BIDARD F C , PEETERS D J , FEHM T , et al . Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data [J ] . Lancet Oncol , 2014 , 15 ( 4 ): 406 - 414 . DOI: 10.1016/S1470-2045(14)70069-5 http://doi.org/10.1016/S1470-2045(14)70069-5 https://linkinghub.elsevier.com/retrieve/pii/S1470204514700695 https://linkinghub.elsevier.com/retrieve/pii/S1470204514700695

HAYES D F , CRISTOFANILLI M , BUDD G T , et al . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival [J ] . Clin Cancer Res , 2006 , 12 ( 14 Pt 1 ): 4218 - 4224 . DOI: 10.1158/1078-0432.CCR-05-2821 http://doi.org/10.1158/1078-0432.CCR-05-2821 https://aacrjournals.org/clincancerres/article/12/14/4218/284794/Circulating-Tumor-Cells-at-Each-Follow-up-Time https://aacrjournals.org/clincancerres/article/12/14/4218/284794/Circulating-Tumor-Cells-at-Each-Follow-up-Time

STOVER D G , PARSONS H A , HA G , et al . Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer [J ] . J Clin Oncol , 2018 , 36 ( 6 ): 543 - 553 . DOI: 10.1200/JCO.2017.76.0033 http://doi.org/10.1200/JCO.2017.76.0033 https://ascopubs.org/doi/10.1200/JCO.2017.76.0033 https://ascopubs.org/doi/10.1200/JCO.2017.76.0033

O'LEARY B , HREBIEN S , MORDEN J P , et al . Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer [J ] . Nat Commun , 2018 , 9 ( 1 ): 896 . DOI: 10.1038/s41467-018-03215-x http://doi.org/10.1038/s41467-018-03215-x https://doi.org/10.1038/s41467-018-03215-x https://doi.org/10.1038/s41467-018-03215-x

PAN H C , GRAY R , BRAYBROOKE J , et al . 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years [J ] . N Engl J Med , 2017 , 377 ( 19 ): 1836 - 1846 . DOI: 10.1056/NEJMoa1701830 http://doi.org/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830 http://www.nejm.org/doi/10.1056/NEJMoa1701830

SLAMON D , EIERMANN W , ROBERT N , et al . Adjuvant trastuzumab in HER2-positive breast cancer [J ] . N Engl J Med , 2011 , 365 ( 14 ): 1273 - 1283 . DOI: 10.1056/NEJMoa0910383 http://doi.org/10.1056/NEJMoa0910383 http://www.nejm.org/doi/10.1056/NEJMoa0910383 http://www.nejm.org/doi/10.1056/NEJMoa0910383

PIETERS R , DE GROOT-KRUSEMAN H , VAN DER VELDEN V , et al . Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group [J ] . J Clin Oncol , 2016 , 34 ( 22 ): 2591 - 2601 . DOI: 10.1200/JCO.2015.64.6364 http://doi.org/10.1200/JCO.2015.64.6364 https://ascopubs.org/doi/10.1200/JCO.2015.64.6364 https://ascopubs.org/doi/10.1200/JCO.2015.64.6364

CHEN X Y , XIE H , WOOD B L , et al . Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia [J ] . J Clin Oncol , 2015 , 33 ( 11 ): 1258 - 1264 . DOI: 10.1200/JCO.2014.58.3518 http://doi.org/10.1200/JCO.2014.58.3518 https://ascopubs.org/doi/10.1200/JCO.2014.58.3518 https://ascopubs.org/doi/10.1200/JCO.2014.58.3518

VAN DALUM G , STAM G J , SCHOLTEN L F A , et al . Importance of circulating tumor cells in newly diagnosed colorectal cancer [J ] . Int J Oncol , 2015 , 46 ( 3 ): 1361 - 1368 . DOI: 10.3892/ijo.2015.2824 http://doi.org/10.3892/ijo.2015.2824 https://www.spandidos-publications.com/10.3892/ijo.2015.2824 https://www.spandidos-publications.com/10.3892/ijo.2015.2824

KREBS M G , SLOANE R , PRIEST L , et al . Evaluation and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer [J ] . J Clin Oncol , 2011 , 29 ( 12 ): 1556 - 1563 . DOI: 10.1200/JCO.2010.28.7045 http://doi.org/10.1200/JCO.2010.28.7045 https://ascopubs.org/doi/10.1200/JCO.2010.28.7045 https://ascopubs.org/doi/10.1200/JCO.2010.28.7045

NG S B , CHUA C , NG M , et al . Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery [J ] . Sci Rep , 2017 , 7 : 40737 . DOI: 10.1038/srep40737 http://doi.org/10.1038/srep40737 https://doi.org/10.1038/srep40737 https://doi.org/10.1038/srep40737

ABBOSH C , BIRKBAK N J , WILSON G A , et al . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [J ] . Nature , 2017 , 545 ( 7655 ): 446 - 451 . DOI: 10.1038/nature22364 http://doi.org/10.1038/nature22364 http://www.nature.com/articles/nature22364 http://www.nature.com/articles/nature22364

GUO N N , LOU F , MA Y F , et al . Circulating tumor DNA detection in lung cancer patients before and after surgery [J ] . Sci Rep , 2016 , 6 : 33519 . DOI: 10.1038/srep33519 http://doi.org/10.1038/srep33519 https://doi.org/10.1038/srep33519 https://doi.org/10.1038/srep33519

TRAPP E , JANNI W , SCHINDLBECK C , et al . Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis [J ] . J Natl Cancer Inst , 2019 , 111 ( 4 ): 380 - 387 . DOI: 10.1093/jnci/djy152 http://doi.org/10.1093/jnci/djy152 https://academic.oup.com/jnci/article/111/4/380/5127124 https://academic.oup.com/jnci/article/111/4/380/5127124

SPARANO J , O'NEILL A , ALPAUGH K , et al . Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial [J ] . JAMA Oncol , 2018 , 4 ( 12 ): 1700 - 1706 . DOI: 10.1001/jamaoncol.2018.2574 http://doi.org/10.1001/jamaoncol.2018.2574 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2574 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2574

GARCIA-MURILLAS I , CHOPRA N , COMINO-MÉNDEZ I , et al . Assessment of molecular relapse detection in early-stage breast cancer [J ] . JAMA Oncol , 2019 , 5 ( 10 ): 1473 . DOI: 10.1001/jamaoncol.2019.1838 http://doi.org/10.1001/jamaoncol.2019.1838 https://jamanetwork.com/journals/jamaoncology/fullarticle/2740685 https://jamanetwork.com/journals/jamaoncology/fullarticle/2740685

LIPSYC-SHARF M , DE BRUIN E C , SANTOS K , et al . Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer [J ] . J Clin Oncol , 2022 , 40 ( 22 ): 2408 - 2419 . DOI: 10.1200/JCO.22.00908 http://doi.org/10.1200/JCO.22.00908 https://ascopubs.org/doi/10.1200/JCO.22.00908 https://ascopubs.org/doi/10.1200/JCO.22.00908

SHAW J , PAGE K , AMBASGER B , et al . Serial postoperative ctDNA monitoring of breast cancer recurrence [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 562 .

ZHOU Q , GAMPENRIEDER S P , FRANTAL S , et al . Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response [J ] . Clin Cancer Res , 2022 , 28 ( 4 ): 697 - 707 . DOI: 10.1158/1078-0432.CCR-21-3231 http://doi.org/10.1158/1078-0432.CCR-21-3231 https://aacrjournals.org/clincancerres/article/28/4/697/678097/Persistence-of-ctDNA-in-Patients-with-Breast https://aacrjournals.org/clincancerres/article/28/4/697/678097/Persistence-of-ctDNA-in-Patients-with-Breast

AVRAHAM A , UHLMANN R , SHPERBER A , et al . Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients [J ] . Int J Cancer , 2012 , 131 ( 7 ): E1166-E1172.

IGNATIADIS M , LITIÈRE S , ROTHE F , et al . Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase Ⅱ trial [J ] . Ann Oncol , 2018 , 29 ( 8 ): 1777 - 1783 . DOI: 10.1093/annonc/mdy211 http://doi.org/10.1093/annonc/mdy211 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341298 https://linkinghub.elsevier.com/retrieve/pii/S0923753419341298

GEORGOULIAS V , BOZIONELOU V , AGELAKI S , et al . Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19 mRNA-positive circulating tumor cells: results of a randomized phase Ⅱ study [J ] . Ann Oncol , 2012 , 23 ( 7 ): 1744 - 1750 . DOI: 10.1093/annonc/mds020 http://doi.org/10.1093/annonc/mds020 https://linkinghub.elsevier.com/retrieve/pii/S0923753419380251 https://linkinghub.elsevier.com/retrieve/pii/S0923753419380251

LIU M C , SHIELDS P G , WARREN R D , et al . Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer [J ] . J Clin Oncol , 2009 , 27 ( 31 ): 5153 - 5159 . DOI: 10.1200/JCO.2008.20.6664 http://doi.org/10.1200/JCO.2008.20.6664 https://ascopubs.org/doi/10.1200/JCO.2008.20.6664 https://ascopubs.org/doi/10.1200/JCO.2008.20.6664

DAWSON S J , TSUI D W , MURTAZA M , et al . Analysis of circulating tumor DNA to monitor metastatic breast cancer [J ] . N Engl J Med , 2013 , 368 ( 13 ): 1199 - 1209 . DOI: 10.1056/NEJMoa1213261 http://doi.org/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261 http://www.nejm.org/doi/10.1056/NEJMoa1213261

PAOLETTI C , MUÑIZ M C , THOMAS D G , et al . Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer [J ] . Clin Cancer Res , 2015 , 21 ( 11 ): 2487 - 2498 . DOI: 10.1158/1078-0432.CCR-14-1913 http://doi.org/10.1158/1078-0432.CCR-14-1913 https://aacrjournals.org/clincancerres/article/21/11/2487/124769/Development-of-Circulating-Tumor-Cell-Endocrine https://aacrjournals.org/clincancerres/article/21/11/2487/124769/Development-of-Circulating-Tumor-Cell-Endocrine

ALLOUCHERY V , BEAUSSIRE L , PERDRIX A , et al . Circulating ESR 1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients [J ] . Breast Cancer Res , 2018 , 20 ( 1 ): 40 . DOI: 10.1186/s13058-018-0968-0 http://doi.org/10.1186/s13058-018-0968-0 https://doi.org/10.1186/s13058-018-0968-0 https://doi.org/10.1186/s13058-018-0968-0

SCHIAVON G , HREBIEN S , GARCIA-MURILLAS I , et al . Analysis of ESR 1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer [J ] . Sci Transl Med , 2015 , 7 ( 313 ): 313ra182.

CHANDARLAPATY S , CHEN D , HE W , et al . Prevalence of ESR 1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial [J ] . JAMA Oncol , 2016 , 2 ( 10 ): 1310 - 1315 . DOI: 10.1001/jamaoncol.2016.1279 http://doi.org/10.1001/jamaoncol.2016.1279 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1279 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1279

MASTORAKI S , STRATI A , TZANIKOU E , et al . ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment [J ] . Clin Cancer Res , 2018 , 24 ( 6 ): 1500 - 1510 . DOI: 10.1158/1078-0432.CCR-17-1181 http://doi.org/10.1158/1078-0432.CCR-17-1181 https://aacrjournals.org/clincancerres/article/24/6/1500/464/ESR1-Methylation-A-Liquid-Biopsy-Based-Epigenetic https://aacrjournals.org/clincancerres/article/24/6/1500/464/ESR1-Methylation-A-Liquid-Biopsy-Based-Epigenetic

FRIBBENS C , GARCIA MURILLAS I , BEANEY M , et al . Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer [J ] . Ann Oncol , 2018 , 29 ( 1 ): 145 - 153 . DOI: 10.1093/annonc/mdx483 http://doi.org/10.1093/annonc/mdx483 https://linkinghub.elsevier.com/retrieve/pii/S0923753419349774 https://linkinghub.elsevier.com/retrieve/pii/S0923753419349774

ARPINO G , BIANCHINI G , MALORNI L , et al . Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor-positive (HR + ), human epidermal growth factor 2-negative (HER2 - ) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial [J ] . J Clin Oncol 2022 , 40 ( 16_suppl ): 1012 .

浏览量

3919

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乳腺癌免疫检查点抑制剂治疗的研究进展与探索方向

中国乳腺癌重要基础转化研究——进展与展望

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

中国年轻女性乳腺癌发病、死亡近30年的变迁情况及趋势研究